Advertisement

NLS

Business article - April 15, 2021

Throwback Thursday: Eugen Steiner – The company doctor

Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap – a family of venture capital funds investing globally in life sciences] is like a company doctor. I deliver […]

Prio - June 11, 2020

Pharma industry confronts growing problem of pharmaceutical waste 

Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health. While pharmaceutical companies are stepping up their efforts to tackle the issue, watchdog organizations, the UN, the […]

Profiles in Business - December 1, 2019

Eugen Steiner: The company doctor

Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap – a family of venture capital funds investing globally in life sciences] is like a company doctor. I deliver […]

Prio - June 18, 2019

Pharma industry confronts growing problem of pharmaceutical waste

Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health.

Profiles in Science - March 7, 2019

Donna Strickland: “It’s all about the science”

Science has always been a driving force in Donna Strickland's life. From the moment she discovered the world of laser physics, she’s been entranced by all the possibilities lasers represent for research, science and medicine.

Biotech article - January 1, 2013

Risky Business

Biotech is an industry with great promise — and great risk. Reaping the benefits of a promising new drug while sidestepping the quicksand of expensive, super-sized failures is no easy feat. In recent years, with a string of high-profile, late-stage drug failures, many venture capitalists jumped ship for safer waters. No one understands this better […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.